Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Black Diamond Therapeutics, Inc. BDTX

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$70.0M
$22.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The company's lead clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The company was founded in 2014 and in 2017, together with Versant Ventures, began building the MAP drug discovery engine to profile oncogenic mutations and create MasterKey Therapies. As of March 11, 2026, the company had 21 full-time employees. The company was formed as an LLC in December 2014 and converted to a corporation in September 2016 under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The company's principal executive offices are located at 245 First Street, 18th Floor, Cambridge, MA 02142.

Written from the business description in Black Diamond Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 March 2026. Every sentence was checked against that document before publication.

Growth

USD 70.0M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 70.0 · Net income 22.4
25.0M50.0M-25.0M-50.0M
2018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

32 cents
of every revenue dollar became profit
ROE
FY2025 · ROE 22.9%
10%20%-20%-40%-60%
201820212025
Three returns, three denominators.

Each USD of equity produced 23 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -62.3
-50M-100M
201820212025

Total assetsUSD 143.0M
EquityUSD 112.2M
CashUSD 21.0M
Current ratio8.42×

Equity funds 78% of total assets.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BDTX, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B0.10.0◌◌◌0.00.00.0
Operating income $B0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.0
EBITDA $B0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.0
Net income $B0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.0
Free cash flow $B◌−0.1−0.1−0.1−0.1−0.1−0.0−0.0
EPS, diluted $0.39−1.27−1.88−2.52−3.47−2.05−16.99−4.42
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %22.9−69.7−70.9−58.5−49.9———
Shares out B0.060.060.050.040.040.040.000.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 32 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 11 checks were skipped: EPS is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image